公开(公告)号：EP1212621A1

公开(公告)日：2002-06-12

申请号：EP00959571.1

申请日：2000-08-29

申请人： SIGNAL PHARMACEUTICALS, INC.

发明人： HOEKSTRA, Merl, F. ,  XIE, Weilin ,  MURRAY, Brion, W. ,  MERCURIO, Frank, M.

IPC分类号： G01N33/68 ,  C12Q1/25 ,  G01N33/50 ,  G01N33/566

CPC分类号： G01N33/74 ,  C12Q1/25 ,  G01N2333/495 ,  G01N2500/10

摘要： Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-β) and members of the TGF-β family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-β family members in a variety of cell types and for therapeutic purposes.

公开(公告)号：EP0920518A1

公开(公告)日：1999-06-09

申请号：EP97938616.0

申请日：1997-08-26

申请人： SIGNAL PHARMACEUTICALS, INC.

发明人： MERCURIO, Frank ,  ZHU, Hengyi ,  BARBOSA, Miguel ,  LI, Gian ,  MURRAY, Brion, W.

IPC分类号： G01N33 ,  A61K38 ,  A61K39 ,  A61K45 ,  A61K48 ,  A61P43 ,  C07K14 ,  C07K16 ,  C12N1 ,  C12N5 ,  C12N9 ,  C12N15 ,  C12P21 ,  C12Q1

CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K14/4702

摘要： Compositions and methods are provided for treating NF-λB-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-λB cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-λB activation.

摘要翻译： 提供用于治疗NF-κB相关病症的组合物和方法。 特别地，本发明提供了一种刺激诱导型IKK信号通路及其组件和变体。 IKK信号或其组分可用于例如鉴定通过NF-κB级联抑制或激活信号转导的抗体和其它调节剂。 IKK信号肽，其组分和/或调节剂也可用于治疗与NF-κB活化相关的疾病。

公开(公告)号：EP1608363A1

公开(公告)日：2005-12-28

申请号：EP04758139.2

申请日：2004-03-24

申请人： SIGNAL PHARMACEUTICALS, INC.

发明人： BENNETT, Brydon, L. ,  BHAGWAT, Shripad, S. ,  MANNING, Anthony, M. ,  MURRAY, Brion, W. ,  O'LEARY, Eoin, C. ,  SATOH, Yoshitaka

IPC分类号： A61K31/416 ,  A61K31/443 ,  A61K31/4525 ,  A61K31/5377 ,  A61P3/04 ,  A61P3/10 ,  A61P29/00 ,  A61P1/00 ,  A61P11/00 ,  A61P17/00 ,  A61P19/00 ,  A61P27/00 ,  A61P37/00

CPC分类号： C07D409/12 ,  A61K31/416 ,  C07D231/54 ,  C07D401/12

摘要： This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

公开(公告)号：EP1212621B1

公开(公告)日：2007-07-25

申请号：EP00959571.1

申请日：2000-08-29

申请人： SIGNAL PHARMACEUTICALS, INC.

发明人： HOEKSTRA, Merl, F. ,  XIE, Weilin ,  MURRAY, Brion, W. ,  MERCURIO, Frank, M.

IPC分类号： G01N33/68 ,  C12Q1/25 ,  G01N33/50 ,  G01N33/566

CPC分类号： G01N33/74 ,  C12Q1/25 ,  G01N2333/495 ,  G01N2500/10

摘要： Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF- beta ) and members of the TGF- beta family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF- beta family members in a variety of cell types and for therapeutic purposes.

公开(公告)号：EP1218347A1

公开(公告)日：2002-07-03

申请号：EP00955709.1

申请日：2000-08-19

申请人： SIGNAL PHARMACEUTICALS, INC.

发明人： BENNETT, Brydon, L. ,  BHAGWAT, Shripad, S. ,  MANNING, Anthony, M. ,  MURRAY, Brion, W. ,  O'LEARY, Eoin, C. ,  SATOH, Yoshitaka

IPC分类号： C07D231/54 ,  C07D401/04 ,  C07D413/04 ,  C07D401/12 ,  C07D409/12 ,  A61K31/415

CPC分类号： C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D409/12 ,  C07D413/04

摘要： Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are pyrazoloanthrone and derivatives thereof having structure (I) wherein R1 and R2 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.